Biomarkers of Intrinsic Angiogenic and Anti-angiogenic Activity in Patients with Endometrial Hyperplasia and Endometrial Cancer

Serum vascular endothelial growth factor (VEGF) and endostatin were determined in postmenopausal women, including 72 with endometrial cancer, 27 with endometrial hyperplasia and 30 healthy controls. Serum VEGF levels in endometrial hyperplasia (142+/-18 ng/ml, mean +/- SE) and endometrial cancer sta...

Full description

Saved in:
Bibliographic Details
Published in:Acta oncologica 2001, Vol.40 (4), p.513-518
Main Author: Mohamed Shaarawy, Sherif A. El-Sharkawy
Format: Article
Language:English
Subjects:
Aged
Biological and medical sciences
Biomarkers, Tumor - blood
Collagen - blood
Endometrial Neoplasms - blood
Endometrial Neoplasms - blood supply
Endometrial Neoplasms - pathology
Endometrial Neoplasms - surgery
Endometrium - pathology
Endostatins
Endothelial Growth Factors - blood
Female
Female genital diseases
Follow-Up Studies
Gynecology. Andrology. Obstetrics
Humans
Hyperplasia
Hysterectomy
Lymphokines - blood
Medical sciences
Middle Aged
Neoplasm Metastasis
Neoplasm Proteins - blood
Neoplasm Staging
Neovascularization, Pathologic - blood
Neovascularization, Pathologic - pathology
Ovariectomy
Peptide Fragments - blood
Postmenopause
Prognosis
Treatment Outcome
Tumors
Vascular Endothelial Growth Factor A
Vascular Endothelial Growth Factors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Serum vascular endothelial growth factor (VEGF) and endostatin were determined in postmenopausal women, including 72 with endometrial cancer, 27 with endometrial hyperplasia and 30 healthy controls. Serum VEGF levels in endometrial hyperplasia (142+/-18 ng/ml, mean +/- SE) and endometrial cancer stages I (291+/-22), II (623+/-68) and stage III-IV (1527+/-119) were significantly higher than the mean for controls (12+/-1.6). Serum endostatin levels in endometrial hyperplasia (149+/-19 ng/ml), endometrial cancer stages I (320+/-41), II (644+/-86) and stage III-IV (1253+/-114) were also significantly higher than the mean for controls (13+/-2.4). Elevated values of VEGF above the non-malignant level were encountered in 7% (stage I), 37% (stage II) and 100% (stage III-IV) of endometrial cancers. The corresponding figures for endostatin were 37%, 59 and 100%, respectively. These results demonstrate that the circulating levels of both markers correlated with tumor stage and apparently tumor burden. Serum VEGF and endostatin levels decreased significantly after treatment, followed by marked elevations at clinical relapse. The VEGF endostatin ratio was higher in the advanced stages ( > 1.0) than in the early stages of endometrial carcinoma (< 1.0). indicating that the balance of angiogenic stimulators and inhibitors may regulate metastasis and access tumor progression.
ISSN:0284-186X
1651-226X
DOI:10.1080/02841860117422